Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Living Cell Technologies
LCT - Living Cell Technologies
News updates: Subscribe
Unsubscribe


June 5, 2008
LCT Expands Diabetes Clinical Trial
June 3, 2008
LCT Lists on International OTCQX
May 21, 2008
LCT interviewed by New Zealand TV program, Close Up
May 12, 2008
LCT presents encapsulation technology at conference
May 8, 2008
LCT features on Channel Ten News
May 8, 2008
LCT prepares to list on international OTCQX
 

How to purchase ADRs

To purchase ADR's, please contact your broker. An ADR is created when a broker purchases LCT shares on the ASX on behalf of a client and delivers those shares to the Bank of New York's local custodian bank, which then instructs the depositary bank to issue Depositary Receipts. The Depositary Receipts may trade freely, like any other security, in the OTC market. The establishment of LCTs sponsored Level 1 ADR program does not involve an offering or issue of new shares.

Benefits of ADRs:

  • US investors often prefer to purchase ADRs rather than ordinary shares in the issuer's home market because ADR's trade, clear and settle according to US market conventions.
  • Easy to trade - quote in US dollars and are as liquid as the underlying security
  • Easy to hold - ADR's settle and clear efficiently and pay dividends in US dollars. Accounting and disclosure in internationally accepted formats.
  • Overcomes obstacles that other funds and institutions may have in purchasing and holding securities outside of their local market.
  • Enables diversification into foreign securities.

For all those US residents willing and able to help LCT by investing in the company, the recently established US ADR (American Depositary Receipt) Investment Program is now effective and fully available. The Bank of New York is currently arranging market makers to streamline the whole process and in the meantime anyone keen on buying (or selling) shares in Living Cell Technologies Limited from the US will be interested in how to invest in the LCT ADRs:

To purchase shares phone your share broker and tell them that "LVCLY" is the symbol for Living Cell Technologies ADRs. One Living Cell Technologies ADR ("LVCLY") is equivalent to 10 Living Cell Technologies shares listed on the ASX ("LCT"). As an example in Australia if the LCT ASX share is at $0.13 per share in Australian dollars, LVCLY will be around $1.04 USD per ADR - being 10 shares. ($1.00 AUD approximately $0.80 USD)

Information on LCT's ADR's including prices quoted and a historical chart of price trends can be found at www.pinksheets.com - just enter the symbol LVCLY. Traded as an OTC stock, it is significant that as a company already listed on the Australian Stock Exchange, LCT complies with the rigorous ASX Listing Rules and Corporate Governance Guidelines, as outlined in LCT's Annual Financial Statements and also importantly LCT's accounts, which are expressed in Australian Dollars, are audited.

Full service share brokers familiar with trading internationally and knowledgeable about ADRs shoud be able to assist interested investors. (However some discount brokerages and on line trading operations may not be as familiar with ADRs).

If you deal with E*Trade you can call E*Trade’s customer service at 678-624-6210 outside the US or 800-387-2331 inside the US.

Should your share broker not be familiar with ADRs the following people will be able to assist you:

Violet Pagan, Vice President Depositary Receipts at the Bank of New York, who can be contacted by phone on : (212) 815 2276, or by
email: vpagan@bankofny.com

Jason Smith, Assistant Treasurer at the Bank of New York, phone
(212) 815 3874, or by email on jsmith@bankofny.com

The team at the Bank of New York are happy to assist brokers and investors with any queries they may have.


About ADRs

ADR Frequently Asked Questions

LCT - Living Cell Technologies
What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors.
>more
   
graphic design and website design - PDF Communications Ltd